• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Strongbridge Biopharma plc

    7/9/21 5:06:20 PM ET
    $SBBP
    Major Pharmaceuticals
    Health Care
    Get the next $SBBP alert in real time by email
    SC 13G 1 strongbridgebiopharma.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. ___)*

     

     

    Strongbridge Biopharma plc

    (Name of Issuer)

     

     

    Ordinary Shares, par value $0.01 per share

    (Title of Class of Securities)

     

     

    G85347105

    (CUSIP Number)

     

     

    July 2, 2021

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [X]       Rule 13d-1(b)

     

    [X]       Rule 13d-1(c)

     

    [ ]       Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

     

     1 
    CUSIP No. G85347105

     

    1.Names of Reporting Persons.

    Stonepine Capital Management, LLC

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization California

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 3,566,964

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 3,566,964
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,566,964

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) IA, OO

     

     2 
    CUSIP No. G85347105

     

    1.Names of Reporting Persons.

    Stonepine Capital, L.P.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization Delaware

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 3,566,964

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 3,566,964
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,566,964

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) PN

     

     3 
    CUSIP No. G85347105

     

    1.Names of Reporting Persons.

    Jon M. Plexico

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 3,566,964

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 3,566,964
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,566,964

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     

     4 
    CUSIP No. G85347105

     

    1.Names of Reporting Persons.

    Timothy P. Lynch

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ______

    (b) X

     

    3. SEC Use Only

     

    4.Citizenship or Place of Organization U.S.A.

     

    Number of

    Shares

    Beneficially

    Owned by

    Each Reporting

    Person With:

    5. Sole Voting Power 3,566,964

     

    6. Shared Voting Power 0

     

    7. Sole Dispositive Power 3,566,964
    8. Shared Dispositive Power 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,566,964

     

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See
    Instructions) ______

     

    11.Percent of Class Represented by Amount in Row (9) 5.3%

     

    12.Type of Reporting Person (See Instructions) HC, IN

     5 
    CUSIP No. G85347105

     

    Item 1.

     

    (a)Name of Issuer

    Strongbridge Biopharma plc

     

    (b)Address of Issuer’s Principal Executive Offices

    900 Northbrook Drive, Suite 200, Trevose, PA 19053

     

     

    Item 2.

     

    (a)The names of the persons filing this statement are:

    Stonepine Capital Management, LLC, a California limited liability company (the “General Partner”)

     

    Stonepine Capital, L.P., a Delaware limited partnership (the “Partnership”)

     

    Jon M. Plexico

     

    Timothy P. Lynch (collectively, the “Filers”)

     

    The General Partner is the general partner and investment adviser of investment funds, including the Partnership. Mr. Plexico and Mr. Lynch are the control persons of the General Partner. The Filers are filing this Schedule 13G jointly, but not as members of a group, and each disclaims membership in a group. Each Filer also disclaims beneficial ownership of the Stock except to the extent of that person’s pecuniary interest therein. In addition, the filing of this Schedule 13G on behalf of the Partnership should not be construed as an admission that it is, and it disclaims that it is, a beneficial owner, as defined in Rule 13d-3 under the Act, of any of the Stock covered by this Schedule 13G.

     

    (b)The principal business office of the Filers is located at

     

    919 NW Bond Street, Suite 204

    Bend, OR 97703-2767

     

    (c)For citizenship of Filers, see Item 4 of the cover sheet for each Filer.

     

    (d)This statement relates to the Issuer’s Ordinary Shares, par value $0.01 per share (the “Stock”).

     

    (e)The CUSIP number of the Issuer is: G85347105

     

     6 
    CUSIP No. G85347105
    Item 3.If this statement is filed pursuant to rule 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)[ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b)[ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c)[ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d)[ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     

    (e)[ X ] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E). As to the General Partner.

     

    (f)[ ] An employee benefit plan or endowment fund in accordance with section 240.13d-1(b)(1)(ii)(F).

     

    (g)[ X ] A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G). As to Mr. Plexico and Mr. Lynch.

     

    (h)[ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i)[ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j)[ ] A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J).

     

    (k)[ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution _______________________________________________________________.

     

    Item 4.Ownership.

     

    See Items 5-9 and 11 of the cover page for each Filer.

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    The Partnership holds the Stock for the benefit of its investors and has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Stock.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     7 
    CUSIP No. G85347105

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.


    Item 10.
    Material to Be Filed as Exhibits

    Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G.

    Item 11.Certification of the General Partner, Mr. Plexico and Mr. Lynch

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

    Certification of the Partnership

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     8 
    CUSIP No. G85347105

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: July 9, 2021

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch

    Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     

     

    /s/ Timothy P. Lynch

     

     9 
    CUSIP No. G85347105

    EXHIBIT A

     

    AGREEMENT REGARDING JOINT FILING

    OF STATEMENT ON SCHEDULE 13D OR 13G

     

    The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection with purchases by the undersigned of the securities of any issuer. For that purpose, the undersigned hereby constitute and appoint Stonepine Capital Management, LLC, a California limited liability company, as their true and lawful agent and attorney-in-fact, with full power and authority for and on behalf of the undersigned to prepare or cause to be prepared, sign, file with the SEC and furnish to any other person all certificates, instruments, agreements and documents necessary to comply with section 13(d) and section 16(a) of the Securities Exchange Act of 1934, as amended, in connection with said purchases, and to do and perform every act necessary and proper to be done incident to the exercise of the foregoing power, as fully as the undersigned might or could do if personally present.

     

    Dated: May 15, 2017

     

     

    STONEPINE CAPITAL MANAGEMENT, LLC


    By: /s/ Timothy P. Lynch
    Managing Member

     

     

    STONEPINE CAPITAL, L.P.

    By: Stonepine Capital Management, LLC,
    General Partner

    By: /s/ Timothy P. Lynch
    Managing Member

     

     
    /s/ Jon M. Plexico
     

     


    /s/ Timothy P. Lynch

     

     

     

    Get the next $SBBP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SBBP

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SBBP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Strongbridge Biopharma downgraded by Craig-Hallum with a new price target

      Craig-Hallum downgraded Strongbridge Biopharma from Buy to Hold and set a new price target of $3.25 from $9.00 previously

      5/25/21 8:44:45 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • Strongbridge Biopharma downgraded by Craig Hallum

      Craig Hallum downgraded Strongbridge Biopharma from Buy to Hold

      5/25/21 8:00:00 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • Strongbridge Biopharma downgraded by JMP Securities

      JMP Securities downgraded Strongbridge Biopharma from Outperform to Market Perform

      5/25/21 7:11:31 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)

      SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)

      1/5/22 12:50:48 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Strongbridge Biopharma plc (Amendment)

      SC 13D/A - Strongbridge Biopharma plc (0001634432) (Subject)

      10/25/21 12:38:25 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Strongbridge Biopharma plc

      SC 13G - Strongbridge Biopharma plc (0001634432) (Subject)

      7/9/21 5:06:20 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Cdk Associates, L.L.C. disposed of 8,060,682 units of Ordinary Shares

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      1/5/22 12:43:50 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Wilhoit Scott L. returned 109,510 units of Ordinary Shares to the company, closing all direct ownership in the company

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      10/6/21 7:43:10 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: Kollender Richard S returned 234,229 units of Ordinary Shares to the company, closing all direct ownership in the company

      4 - Strongbridge Biopharma plc (0001634432) (Issuer)

      10/6/21 7:42:51 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Xeris Pharmaceuticals Completes Acquisition of Strongbridge Biopharma

      Xeris Pharmaceuticals, Inc. and Strongbridge Biopharma plc are now subsidiaries of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Xeris Pharmaceuticals, Inc. ("Xeris"), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that it has successfully completed the previously announced acquisition of Strongbridge Biopharma plc (NASDAQ:SBBP) ("Strongbridge"). Under the terms of the acquisition agreement, the businesses of Xeris and Strongbridge are now combined under Xeris Biopharma Holdings, Inc. ("Xeris Biopharma Holdings"). Strongbridge shares and Xeris shares ceased trading on the

      10/5/21 4:05:00 PM ET
      $SBBP
      $XERS
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Strongbridge Biopharma plc Announces Completion of Acquisition by Xeris Pharmaceuticals, Inc.

      DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) ("Xeris") by means of a scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The Court sanction hearing in relation to the Scheme was held earlier today at which the Court sanctioned the Scheme and confirmed the related reduction of capital. The Scheme became effective earlier today on October 5, 2021 upon the r

      10/5/21 4:01:00 PM ET
      $SBBP
      $XERS
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Strongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.

      DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the "Company" or "Strongbridge") today announced that the High Court of Ireland (the "Court") has set the date of the final court hearing to sanction the proposed acquisition of Strongbridge by Xeris Pharmaceuticals, Inc. ("Xeris") by means of scheme of arrangement (the "Scheme") under Chapter 1 of Part 9 of the Irish Companies Act 2014 (the "Act"). The court hearing to sanction the Scheme is scheduled to be heard in the Commercial List of the Court sitting at the Four Courts, Inns Quay, Dublin 7, Ireland at 11:00 a.m. (Irish time) on October 5, 2021, and the Scheme is expected t

      9/23/21 4:01:00 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care

    $SBBP
    Leadership Updates

    Live Leadership Updates

    See more

    $SBBP
    SEC Filings

    See more
    • Axogen, Inc. Appoints John H. Johnson to Board of Directors

      ALACHUA, Fla. and TAMPA, Fla., July 19, 2021 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for damage or discontinuity to peripheral nerves, today announced that John H. Johnson has been appointed to its Board of Directors, effective July 19, 2021. Johnson will serve on both the Governance, Nominating and Sustainability Committee and the Science and Technology Committee. Johnson is a recognized leader in the biopharmaceutical industry with more than 30 years of experience in senior leadership positions, including at Johnson & Johnson, Eli Lilly & Company, ImClone, and Centocor Ortho Biotech. "John is an excellent

      7/19/21 4:01:00 PM ET
      $VSTM
      $AXGN
      $SBBP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Major Pharmaceuticals
    • SEC Form 15-12B filed by Strongbridge Biopharma plc

      15-12B - Strongbridge Biopharma plc (0001634432) (Filer)

      10/15/21 4:16:11 PM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Strongbridge Biopharma plc

      EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)

      10/7/21 12:15:19 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Strongbridge Biopharma plc

      EFFECT - Strongbridge Biopharma plc (0001634432) (Filer)

      10/7/21 12:15:12 AM ET
      $SBBP
      Major Pharmaceuticals
      Health Care